# Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

> **NCT00866775** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 193 (actual)

## Conditions studied

- Epilepsy With Simple or Complex Partial Onset Seizures

## Interventions

- **DRUG:** Eslicarbazepine acetate
- **DRUG:** Eslicarbazepine acetate

## Key facts

- **NCT ID:** NCT00866775
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 193 (ACTUAL)
- **Last updated:** 2016-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00866775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00866775, "Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00866775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*